



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



13-Docosenamide

Item No. 90377

CAS Registry No.: 112-84-5
Formal Name: 13Z-docosenamide
Synonyms: Armoslip E, *cis*-13-Docosenamide, Erucamide
MF: C₂₂H₄₃NO
FW: 337.6
Purity: ≥98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥1 year



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

13-Docosenamide is supplied as a crystalline solid. A stock solution may be made by dissolving the 13-docosenamide in the solvent of choice. 13-Docosenamide is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of 13-docosenamide in these solvents is approximately 22, 20, and 14 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of 13-docosenamide can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of 13-docosenamide in PBS, pH 7.2, is approximately 0.05 mg/ml. Store aqueous solutions of 13-docosenamide on ice and use within 12 hours of preparation. Although the aqueous solutions of 13-docosenamide may be stable for more than 12 hours, we strongly recommend using a fresh preparation each day.

Description

13-Docosenamide is the amide of docosenoic acid. It was first identified in the cerebrospinal fluid of sleep-deprived cats. It has also been detected in the cerebrospinal fluid of rats and humans.¹ 13-Docosenamide causes reduced mobility and slightly lessened awareness in rats, whereas, 9-octadecenamide induces physiological sleep.

Reference

1. Cravatt, B.F., Prospero-Garcia, O., Siuzdak, G., *et al.* Chemical characterization of a family of brain lipids that induce sleep. *Science* **268**, 1506-1509 (1995).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/29/2018

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM